Loading in 2 Seconds...
Loading in 2 Seconds...
Unveiling th e WTO August 30 Decision: The Canadian Experience. Rachel Kiddell-Monroe President, Universities Allied for Essential Medicines; Former Coordinator for MSF’s Access to Essential Medicines Campaign in Canada. Canada’s Pledge to Africa.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
President, Universities Allied for Essential Medicines; Former Coordinator for MSF’s Access to Essential Medicines Campaign in Canada
“…the use of patents for international humanitarian purposes to address public health problems”
Apotex: US$0.195 cents per tablet (US$0.39/day)
US$143/year per patient
US$176/year per patient
- economies of scale
- need for stockpiling
Clear royalty formula (sliding scale based on country ranking on UN Development Index to max of 4%)
30 day limit on voluntary licence negotiations (but only starting from the date that all of the information is provided to the patent-holder, including the quantity, name of the country, etc).
MSF Faxes order
estimated date of
arrival in project
August 30 Decision is not an expeditious solution to the access to medicines crisis
Up to 21,000 Rwandan patients have access to treatment they need
Another affordable treatment option available
One developed country generic company shown to have capacity and will to provide low cost, high quality medicines
Extra competition on this drug which brought price down
7 years after Doha declared access for all
5 years after August 30 Decision promised a mechanism to allow generic drug production for developing countries
And more than 4 years after Canadian legislation enacted
70% of patients needing ART still do not have access to treatment
No other country or company tried to use legislation either in Canada or in the other countries which have also adopted legislation.
Historically easy access to Indian drugs clearly demonstrates limitations of WTO process.
‘If other critical medicines are to go to Africa in a reasonable timeframe, the Federal Government must change the CAMR Legislation. CAMR is unworkable as it now stands’ Jack Kay, Apotex President and COO
Canadian NGOs, activists, students and Canadian media. Notable role of Richard Elliott of Canadian HIV/AIDS Legal Network, Stephen Lewis and the Global Treatment Action Group
New network of Grandmothers-for-Africa groups across Canada raising this issue in international fora, in meetings with parliamentarians, keeping it in the media, gathering thousands of signatures on a petition to Parliament
Legal Network have presented Canadian Parliament with detailed proposals for legislative reform.
For more resources go to www.aidslaw.ca/gtag.